정맥혈전색전증 예방 세계 시장 규모는 2024년 68억 2,000만 달러로 평가되며, 2030년까지 5.58%의 CAGR로 예측 기간 동안 94억 6,000만 달러에 달할 것으로 예상됩니다.
정맥혈전색전증(VTE) 예방 시장은 심부정맥혈전증(DVT)과 폐색전증(PE)의 발생률이 증가하고 있으며, 특히 입원 환자 및 수술 후 환자에서 심각한 건강상의 위험을 초래함에 따라 꾸준한 성장세를 보이고 있습니다. 치료되지 않은 VTE에 따른 합병증에 대한 인식이 높아지면서 항응고제와 같은 약리학적 개입과 압박 장치와 같은 기계적 방법을 포함한 예방적 수단이 널리 채택되고 있습니다. 의료 인프라의 확대와 진단 기술의 발전으로 위험에 처한 환자를 조기에 발견하고 치료할 수 있게 되었습니다. 병원 및 외래 진료 환경에서 환자 안전 프로토콜에 대한 중요성이 높아지면서 VTE 예방책의 채택이 더욱 확대되고 있습니다. 인공지능(AI)과 예측 분석의 통합으로 고위험군 환자 식별에 인공지능(AI)과 예측 분석이 접목되어 치료 결과를 개선하고 자원 배분을 최적화할 수 있게 되었습니다.
| 시장 개요 | |
|---|---|
| 예측 기간 | 2026-2030년 |
| 시장 규모 : 2024년 | 68억 2,000만 달러 |
| 시장 규모 : 2030년 | 94억 6,000만 달러 |
| CAGR : 2025-2030년 | 5.58% |
| 급성장 부문 | 외래 의료 센터 |
| 최대 시장 | 북미 |
암, 심혈관질환, 비만과 같은 만성질환의 유병률 증가는 효과적인 VTE 예방에 대한 수요 증가에 기여하고 있습니다. 기존 항응고제를 대체할 수 있는 보다 안전하고 편리한 대안으로 직접 경구용 항응고제(DOAC)의 채택이 증가하고 있습니다. 외래 치료와 최소침습 수술로의 전환은 병원 환경 이외의 예방 조치의 필요성을 가속화하고 있습니다. 간헐적 공기압박(IPC) 시스템이나 단계적 압박 스타킹과 같은 기계적 예방 장치의 기술 발전으로 환자의 순응도와 예후가 개선되고 있습니다. 혈전 예방을 장려하는 의료 정책 및 상환 프로그램이 시장 성장을 촉진하고 있습니다. 생물학적 제제 및 차세대 항응고제 연구로 인해 효과적인 혈전 예방을 보장하면서 출혈 위험을 줄일 수 있는 혁신적인 치료 옵션이 도입될 것으로 기대되며, VTE에 취약한 노년층이 증가함에 따라 예방 요법에 큰 성장 잠재력을 가지고 있습니다.
신흥국 시장에서는 VTE 예방에 대한 인지도와 접근성에 한계가 있어 시장 확대에 큰 걸림돌이 되고 있습니다. 새로운 항응고 요법 및 기계 장치와 관련된 높은 비용으로 인해 특히 저소득층의 접근성을 제한하고 있습니다. 출혈 위험과 항응고제의 잠재적 부작용에 대한 우려로 인한 환자들의 망설임이 채택률에 영향을 미치고 있습니다. 신약 및 의료기기의 까다로운 승인 절차로 인해 시장 진입이 지연되고, 첨단 예방법 선택이 제한됩니다. 특정 의료기관에서 VTE 예방 가이드라인을 준수하지 않아 예방 전략의 실행이 일관성 없이 이루어지고 있습니다. 여러 합병증을 동반한 환자의 VTE 위험 관리의 복잡성은 의료진에게 또 다른 도전 과제를 안겨주고 있습니다. 세계 정맥혈전색전증 예방 시장의 지속적인 성장을 위해서는 이러한 장벽을 극복하기 위해 대상별 교육 프로그램, 비용 효율적인 치료 솔루션, 간소화된 규제 경로를 통해 이러한 장벽을 극복하는 것이 매우 중요합니다.
인구 고령화
예방 비용
디지털 헬스 통합
Global Venous Thromboembolism Prophylaxis Market was valued at USD 6.82 Billion in 2024 and is expected to reach USD 9.46 Billion in the forecast period with a CAGR of 5.58% through 2030. The Global Venous Thromboembolism (VTE) Prophylaxis Market is witnessing steady growth due to the rising incidence of deep vein thrombosis (DVT) and pulmonary embolism (PE), which pose significant health risks, particularly among hospitalized and post-surgical patients. Increased awareness of the complications associated with untreated VTE has led to the widespread adoption of prophylactic measures, including pharmacological interventions such as anticoagulants and mechanical methods like compression devices. The expansion of healthcare infrastructure and advancements in diagnostic technologies are enabling early detection and treatment of at-risk patients. Growing emphasis on patient safety protocols in hospitals and ambulatory care settings is further driving the adoption of VTE prophylaxis. The integration of artificial intelligence (AI) and predictive analytics in identifying high-risk individuals is improving treatment outcomes and optimizing resource allocation.
| Market Overview | |
|---|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 6.82 Billion |
| Market Size 2030 | USD 9.46 Billion |
| CAGR 2025-2030 | 5.58% |
| Fastest Growing Segment | Ambulatory care Centers |
| Largest Market | North America |
Increasing prevalence of chronic diseases such as cancer, cardiovascular disorders, and obesity is contributing to the rising demand for effective VTE prophylaxis. The adoption of direct oral anticoagulants (DOACs) as a safer and more convenient alternative to traditional anticoagulants is gaining traction. The shift towards outpatient care and minimally invasive surgeries is accelerating the need for preventive measures beyond hospital settings. Technological advancements in mechanical prophylaxis devices, such as intermittent pneumatic compression (IPC) systems and graduated compression stockings, are improving patient compliance and outcomes. Healthcare policies and reimbursement programs promoting thromboprophylaxis are strengthening market growth. Increasing research in biologics and next-generation anticoagulants is expected to introduce innovative treatment options, reducing bleeding risks while ensuring effective clot prevention. The rising geriatric population, which is more susceptible to VTE, presents significant growth potential for prophylactic therapies.
Limited awareness and accessibility of VTE prophylaxis in developing regions remain significant barriers to market expansion. High costs associated with novel anticoagulant therapies and mechanical devices restrict affordability, particularly in low-income populations. Patient hesitation due to concerns about bleeding risks and potential side effects of anticoagulants affects adoption rates. Stringent regulatory approval processes for new drugs and devices lead to delays in market entry, limiting the availability of advanced prophylactic options. The lack of adherence to VTE prevention guidelines in certain healthcare facilities results in inconsistent implementation of prophylaxis strategies. The complexity of managing VTE risks in patients with multiple comorbidities poses additional challenges for healthcare providers. Addressing these barriers through targeted awareness programs, cost-effective treatment solutions, and streamlined regulatory pathways will be crucial for the sustained growth of the Global Venous Thromboembolism Prophylaxis Market.
Key Market Drivers
Aging Population
The aging population is a significant driving force behind the growth of the Global Venous Thromboembolism (VTE) Prophylaxis Market. As the global population continues to age, there is a marked increase in the incidence of VTE-related health issues, such as deep vein thrombosis (DVT) and pulmonary embolism (PE). Elderly individuals are particularly vulnerable to VTE due to factors like reduced mobility, comorbidities, and alterations in blood composition. This demographic shift has led to a heightened demand for effective VTE prophylactic measures.
One primary reason for this increased demand is the higher prevalence of surgical procedures among older individuals. Surgical interventions, especially orthopedic and major surgeries, are known risk factors for VTE. The elderly population frequently undergoes joint replacements, cardiac surgeries, and other medical interventions, increasing their risk. Healthcare providers are acutely aware of this risk and are increasingly implementing prophylactic strategies, such as anticoagulant medications and mechanical devices, to minimize the likelihood of VTE in their elderly patients.
Furthermore, the elderly population's vulnerability to VTE is exacerbated by decreased mobility and lifestyle changes. Reduced physical activity and prolonged periods of immobility, such as extended bed rest or long flights, can significantly elevate the risk of blood clots. As the aging population seeks to maintain their mobility and quality of life, the demand for VTE prophylaxis becomes even more critical.
Pharmaceutical companies have responded to this growing need by developing anticoagulant medications with improved safety profiles and dosing regimens suitable for older patients. Additionally, medical device manufacturers have introduced more comfortable and efficient mechanical prophylaxis devices, ensuring that VTE prevention options are well-suited for elderly individuals.
Key Market Challenges
Cost of Prophylaxis
The price tag associated with VTE prevention, especially in the case of anticoagulant medications and mechanical devices, can be overwhelming for both healthcare systems and patients. This becomes particularly evident in regions with limited healthcare budgets or in countries where out-of-pocket expenses for medical treatments are high. Such expenses can deter individuals from seeking prophylactic measures, even when they are at risk of developing VTE.
Anticoagulant medications, while effective, often come with a high cost, especially the newer, more advanced drugs with better safety profiles and fewer side effects. For many patients, these medications need to be taken long-term, leading to escalating costs over time. Additionally, mechanical prophylaxis devices, such as intermittent pneumatic compression (IPC) pumps or advanced compression stockings, can also be pricey. While these devices are vital for patients who cannot take anticoagulants due to contraindications, their costs can be a significant barrier to widespread adoption.
Furthermore, the financial implications of VTE prophylaxis are not limited to the direct cost of medications and devices. Monitoring patients, especially those on anticoagulant medications, requires regular blood tests and follow-ups, incurring additional expenses. For many patients, especially those without comprehensive insurance coverage, these cumulative costs can be daunting.
Key Market Trends
Digital Health Integration
Digital health integration is emerging as a pivotal driver behind the growth of the Global Venous Thromboembolism (VTE) Prophylaxis Market. VTE, encompassing deep vein thrombosis (DVT) and pulmonary embolism (PE), affects up to 900,000 Americans annually, with an estimated 60,000 to 100,000 deaths each year. The integration of digital health technologies is revolutionizing VTE prophylaxis management, leading to more effective prevention and improved patient outcomes.
Electronic health records (EHRs) serve as a cornerstone in this integration, enabling healthcare providers to swiftly access patient histories, risk factors, and medication profiles. This real-time data access facilitates timely risk assessments, ensuring high-risk patients receive appropriate prophylactic measures. Studies have shown that implementing EHRs can reduce medication errors by 54% and adverse drug reactions by 36%, thereby enhancing patient safety.
Remote patient monitoring systems also play a vital role in enhancing VTE prevention. These systems allow continuous monitoring of patients post-discharge, tracking activity levels, vital signs, and medication adherence. Such surveillance is crucial, as more than one-third of VTE cases are associated with recent hospitalizations, with many events occurring after discharge. By detecting early warning signs of VTE development, healthcare teams can intervene promptly, significantly reducing incidence rates and improving patient safety.
Telemedicine platforms further contribute to VTE prophylaxis by facilitating virtual consultations, enabling healthcare providers to assess risk factors and guide prophylactic measures remotely. This approach is particularly beneficial given that as many as 70% of healthcare-associated VTE cases are preventable through measures such as anticoagulant medications or compression stockings. Remote consultations enhance patient education and engagement, promoting adherence to preventive strategies.
In this report, the Global Venous Thromboembolism Prophylaxis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Venous Thromboembolism Prophylaxis Market.
Global Venous Thromboembolism Prophylaxis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: